Analyst Ratings For Intra-Cellular Therapies (NASDAQ:ITCI)
Today, Royal Bank of Canada initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform with a price target of $33.00.
Some recent analyst ratings include
- 2/8/2018-Royal Bank of Canada initiated coverage with a Outperform rating.
- 12/15/2017-Canaccord Genuity initiated coverage with a Buy rating.
- 11/8/2017-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
- 9/8/2017-BTIG Research Reiterated Rating of Buy.
- 9/8/2017-Cowen Reiterated Rating of Outperform.
- 9/7/2017-Piper Jaffray Companies Upgrade from a “Neutral ” rating to a ” Overweight” rating.
- 8/24/2017-JMP Securities Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI) has insider ownership of 19.80% and institutional ownership of 74.37%.
- On 1/22/2018 Michael Halstead, SVP, sold 25,500 with an average share price of $18.03 per share and the total transaction amounting to $459,765.00.
- On 1/8/2018 Kimberly E Vanover, SVP, sold 772 with an average share price of $17.46 per share and the total transaction amounting to $13,479.12.
- On 1/8/2018 Sharon Mates, Chairman, sold 6,604 with an average share price of $17.48 per share and the total transaction amounting to $115,437.92.
- On 1/5/2018 Kimberly E Vanover, SVP, sold 1,185 with an average share price of $17.37 per share and the total transaction amounting to $20,583.45.
- On 1/5/2018 Sharon Mates, Chairman, sold 11,257 with an average share price of $17.08 per share and the total transaction amounting to $192,269.56.
- On 1/4/2018 Lawrence J Hineline, CFO, sold 3,192 with an average share price of $15.67 per share and the total transaction amounting to $50,018.64.
- On 12/29/2017 Christopher D Alafi, Director, bought 1,001 with an average share price of $14.48 per share and the total transaction amounting to $14,494.48.
Recent Trading Activity for Intra-Cellular Therapies (NASDAQ:ITCI)
Shares of Intra-Cellular Therapies closed the previous trading session at 16.77 up +0.38 2.32% with 16.530000686645508 shares trading hands.